

Special Issue

Molecular Genetics of Psychiatric Pathology

Message from the Guest Editors

Psychiatric disorders, including schizophrenia, major depression and bipolar disorder, are the leading cause of disability worldwide. Despite the substantial progress achieved through several genetic studies that allowed the identification of over one hundred loci associated with major psychiatric disorders, the understanding of their biological meaning remains limited. Moreover, genetic variability has been also shown to partially account for the observed interindividual differences in disease features and in therapeutical responses, even though the underlying mechanisms are still largely unclear. These missing pieces represent an obstacle to the advancement of precision medicine in psychiatry.

This Special Issue aims to explore the molecular genetic underpinnings of psychiatric disorders. Original research and reviews addressing the identification of genetic risk factors related to psychiatric disorders and related endophenotypes are welcome. Genome-wide association studies (GWAS) and pharmacogenetic studies will be particularly appreciated. We also warmly encourage you to propose novel functional studies to untangle the complex etiology of psychiatric disorders.

Guest Editors

Dr. Vincenzo Dattilo

Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catan-Zaro, Viale Europa—Germaneto, 88100 Catanzaro, Italy

Dr. Elisabetta Maffioletti

Department of Theoretical and Applied Sciences, eCampus University, Novedrate, Como, Italy

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/162123

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).